We are proud to announce our participation in the CHANGE project
May 4th, 2023, Vienna, Austria
The CHANGE project focuses on the basic biology of ageing to uncover its multi-systemic signatures, determine the extent to which senescence is linked to clinically distinct connective tissue (CT) disorders within the programme and potentially develop novel therapeutics targeting pathways involved in CT diseases.
Evercyte’s role will be to target cellular senescence using MSC-derived EVs as potential senomorphics in different age-associated connective tissue disorders.
The project has received funding from the Horizon Europe MSCA Doctoral Network (grant number 101072766).